Evotec Shareholders Clear New Board Leadership as €75m Cost Drive Gathers Pace
12.06.2026 - 16:35:07 | boerse-global.de
Evotec’s annual general meeting in Hamburg delivered a decisive mandate for change on Thursday, with shareholders overwhelmingly endorsing a reshaped supervisory board. Dieter Weinand, the former Biogen executive long tipped for the role, formally replaced Iris Löw-Friedrich as chairman, while Wolfgang Hofmann secured a new seat on the panel. Duncan McHale and Wesley Wheeler retained their existing mandates. The broad approvals — backed by roughly 43% of voting capital — signal investor confidence in a leadership reset that will now steer the company through an ambitious restructuring.
The fresh oversight team inherits a business in the thick of a turnaround. First-quarter revenue slumped nearly 22% year-on-year, dragging operating earnings deep into negative territory. Management’s response is the “Horizon” programme, a sweeping cost-reduction effort targeting €75m in annual savings by the end of 2027. The board expects the first tangible financial benefits to emerge as early as the second half of this year, though the timeline remains ambitious given the scale of the cuts.
Weinand’s appointment brings deep sector experience to a pivotal moment. Life-science companies are increasingly leaning on platform technologies and robust patent portfolios to weather a turbulent biotech market, and Evotec aims to reinforce its position as a leading drug-discovery partner. Analysts view the new chairman as capable of providing the operational stability needed to execute that strategy more effectively.
Should investors sell immediately? Or is it worth buying Evotec?
The stock’s reaction has been muted. Shares closed Thursday at €4.77, trimming the year-to-date decline to around 14%. Over the past twelve months, the paper has shed nearly 37% of its value. A modest bright spot: the last 30 days produced a gain of roughly 4%, though the price still languishes below key technical thresholds. The 50-day moving average sits at €5.03, acting as a near-term resistance that, if breached, could improve the chart outlook. With an annualised volatility of 46%, the stock remains a high-beta play that demands close monitoring.
Despite the sluggish start to the year, management has held firm on its full-year guidance, betting heavily on a stronger second half. The new supervisory board will be tasked with holding the executive team to that promise — and with ensuring the Horizon plan delivers on its headline savings figure without derailing the company’s core pipeline ambitions.
Ad
Evotec Stock: New Analysis - 12 June
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
